Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.40p -0.21% 1,646.40p 1,643.40p 1,644.00p 1,662.40p 1,639.00p 1,654.00p 7,731,290 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.3 81,735

Glaxosmithkline Share Discussion Threads

Showing 19576 to 19597 of 19875 messages
Chat Pages: 795  794  793  792  791  790  789  788  787  786  785  784  Older
DateSubjectAuthorDiscuss
01/5/2019
12:09
With these results she should be dishing out caviar.
abdullla
01/5/2019
08:52
Yes, but Emma will be serving tea and biscuits during the webcast at 14.00 BST
tradermichael
01/5/2019
08:51
They need to sort out their manufacturing problems !
gbh2
01/5/2019
08:36
Yes you better have the tea trolley ready when the masters wake up.
abdullla
01/5/2019
08:35
12.00 GMT last year :-)
sicker
01/5/2019
07:50
yes, but I think they wait until the US wakes up.
thamestrader
01/5/2019
07:49
Are results due out today?
jadeticl3
01/5/2019
07:05
2 weeks to next x-dividend …… ;0)
tradermichael
30/4/2019
21:10
TM - will they all be additional sales or will some of those new sales come from existing drugs (sales)?
alphorn
30/4/2019
21:07
Some of the world’s largest drugmakers painted an optimistic picture of the industry’s prospects this year, after posting better than expected first-quarter earnings thanks to growth in China and new cancer treatments. Pfizer, Merck and Eli Lilly all increased their earnings forecasts for 2019 on Tuesday, even as investors continue to worry about the prospect of US regulation on drug prices and US presidential candidates pledge to transform the healthcare system. hTTps://www.ft.com/content/ea5ec5c8-6b63-11e9-80c7-60ee53e6681d Interesting comment vis earnings forecasts UP despite fear over US regulation on drug prices.....
crossing_the_rubicon
29/4/2019
18:23
Not sure what you mean?
tradermichael
29/4/2019
14:01
TM - will that be incremental sales or cannibalisation?
alphorn
29/4/2019
13:57
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
tradermichael
27/4/2019
08:39
The U.S. Food and Drug Administration on Friday said it approved GlaxoSmithKline PLC's (GSK) Benlysta, or belimumab, intravenous infusion to treat children with systemic lupus erythematosus, commonly known as lupus. This is the first time the administration approved a treatment for pediatric patients with lupus, it said. Benlysta has been approved for use in adult patients since 2011. The FDA said childhood-onset SLE is rare, but is generally more active in children and adolescents than adult patients. As a result of the disease starting early in life, pediatric patients have a higher risk for developing increased organ damage and complications from the disease.
tradermichael
25/4/2019
08:27
Shingrix is in favour, though ….. GlaxoSmithKline̵7;s new shingles vaccine Shingrix hit the market running, performing so well in its launch year that the drugmaker ran into supply constraints. In response, GSK has pledged to boost its capacity, and it's now investing $100 million in vaccine production in Montana. GSK on Wednesday unveiled a $100 million investment to an existing site in Hamilton, Montana, where it makes adjuvants used in several of its vaccines. The expansion will add permanent jobs at the site as well as temporary construction and contracting work. The company’s site in Hamilton, Montana currently employs around 200 people. The site has produced adjuvants for GSK vaccines for more than a decade, GSK U.S. president of pharmaceuticals Jack Bailey said in a statement. "By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix,” Bailey added. The investment comes after a huge launch year for Shingrix, during which the vaccine pulled in £784 million ($1 billion). Execs have committed to continue expanding production capacity to avoid last year's supply issues. In response to short supply, the company delayed TV advertising and implemented order limits for its vaccines. As of the end of December, GSK has distributed more than 8.5 million doses of the vaccine, a spokesman said. The company plans to ship a "significantly" higher number of doses this year. On a conference call last year, GSK's global pharmaceuticals president Luke Miels said the company can "pretty much sell anything that we can make now in the U.S."
tradermichael
24/4/2019
14:49
Pharma's are so out of favour in the US, price going lower boys.
montyhedge
24/4/2019
11:39
3 weeks to ex-dividend …… ;0)
tradermichael
18/4/2019
23:17
Market report: Drug makers dragged on the FTSE 100, which ended down 0.2 per cent or 11.44 points, at 7459.88, after healthcare reform proposals from US Democratic presidential candidates sparked a sell-off. https://www.dailymail.co.uk/money/markets/article-6937273/MARKET-REPORT-Online-lending-platform-Funding-Circle-track-3-4bn-worth-loans.html
philanderer
18/4/2019
11:26
Redundancies are being made at pharmaceutical giant GlaxoSmithKline in Stevenage as part of “a new approach to research and development”. https://www.thecomet.net/news/redundancies-announced-at-glaxosmithkline-1-5999673
zho
18/4/2019
11:24
Read last night somewhere about redundancies in Stevenage?
alphorn
17/4/2019
14:02
I will do so Toffeeman if I don’t get a sensible reply from buywell.
jadeticl3
17/4/2019
10:46
jad - simple - use the filter - s/he is bonkers
toffeeman
Chat Pages: 795  794  793  792  791  790  789  788  787  786  785  784  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190721 23:01:36